Proactive Investors - Run By Investors For Investors

Silence Therapeutics finance chief departs

Silence’s group head of financial planning and analysis, Rob Quinn, will take on the outgoing David Ellam’s responsibilities for the time being whilst a permanent successor is found
director leaving office
CEO David Horn Solomon wished Ellam all the best for the future

The chief financial officer of Silence Therapeutics PLC (LON:SLN), David Ellam, has left the gene editing specialist with immediate effect.

Silence’s group head of financial planning and analysis, Rob Quinn, will take on Ellam’s responsibilities for the time being whilst a permanent successor is found.

READ: Silence adds new siRNA asset to pre-clinical pipeline

“On behalf of the board I would like to thank David for his contribution to Silence,” said chief executive David Horn Solomon.

“He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space. We wish David every success for the future.”

View full SLN profile View Profile

Silence Therapeutics plc Timeline

Related Articles

Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use